What happened
CytoSorbents Corporation (NASDAQ: CTSO) agreed to a $6.25 million financing that would pay down its Avenue Capital Group loan with cash and stock. The planned repayments would cut principal from $17.5 million before the Nov. 19 agreement to $12.25 million, a 30.0% drop, OptimistFi calculates.
Shareholders face dilution in exchange for lower borrowing costs. The registered direct offering of shares and pre-funded warrants would raise about $4 million before expenses and about $3.5 million after them. Existing shareholders, management and directors subscribed for about three-quarters of the offering.
Most of the net proceeds would go to Avenue Capital Group. CytoSorbents plans to repay $3 million of principal in cash and make a $52,500 prepayment fee payment and a $270,000 final payment. Avenue Venture Opportunities Fund, L.P. would take 455,465 shares in exchange for $2.25 million of principal.
Why it matters
CytoSorbents expects to save about $700,000 in interest over 12 months. The amendment moves the due date from July 1, 2027, to July 1, 2028, and extends interest-only payments through March 31, 2028.
The amendment also gives CytoSorbents more room under its cash-burn covenant. The threshold rises to $3.2 million for testing periods through Dec. 31 and is $2 million otherwise.
Further debt relief could dilute shareholders again. Lenders can convert part of the principal into stock at $6.92 a share. They can convert another portion at $8.65 a share starting Jan. 1, 2028, or sooner if the FDA grants marketing approval for DrugSorb-ATR.
In OptimistFi's view, the lower debt load helps, but CytoSorbents still needs wider use of its blood purification devices in intensive care and cardiac surgery to outpace cash burn.
What's next
The offering is expected to close on or about Nov. 20 if standard closing conditions are met. The principal will fall only once CytoSorbents makes the cash repayment and completes the stock exchange. Both are expected around the same time as the offering close.

